These results are notable in light of the recent clinical observation that ASPS is one of the most clinically responsive tumor types to checkpoint inhibitor therapy (Wilky et al., 2019), and the association between expression of major histocompatibility complex (MHC) molecules and efficacy of checkpoint inhibitory therapies (Yuasa et al., 2017). The gene discussed is HLA-C; the disease is alveolar soft part sarcoma.